| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 公司从自身核心优势出发，主要业务聚焦于抗HIV及人源蛋白领域，公司通过不断积累与持续投入，在这两个优势赛道上进一步优化在研管线、提升商业化运营能力，取得了阶段性成果，公司核心竞争力不断增强。 公司在研项目19项，核心包括8个1类新药和2个2类新药；公司首款抗艾滋病1类创新药艾诺韦林片已获批上市并进入商业化阶段，公司第二款抗艾滋病1类创新药艾诺米替片于2022年12月获批上市。 | ||||||||||||||||||||||||
| Main Business | 聚焦于抗HIV及人源蛋白领域。 | ||||||||||||||||||||||||
| Legal Representative | 傅和亮 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 刘艳 | ||||||||||||||||||||||||
| Solicitors | 上海澄明则正律师事务所 | ||||||||||||||||||||||||
| Auditors | 容诚会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 0514-82090238 | ||||||||||||||||||||||||
| Fax No | 0514-87736366 | ||||||||||||||||||||||||
| Website | www.aidea.com.cn | ||||||||||||||||||||||||
| ad@aidea.com.cn | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 20/07/2020 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ -0.180 | ||||||||||||||||||||||||
| DPS(RMB)* | -- | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 2.675 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 3.854B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |